Strong Tower Advisory Services Takes $884,000 Position in TransMedics Group, Inc. $TMDX

Strong Tower Advisory Services acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 8,891 shares of the company’s stock, valued at approximately $884,000.

Several other large investors have also modified their holdings of the company. Corient Private Wealth LLC raised its holdings in TransMedics Group by 32.5% in the 4th quarter. Corient Private Wealth LLC now owns 3,084 shares of the company’s stock worth $375,000 after acquiring an additional 757 shares during the period. Pacer Advisors Inc. bought a new stake in TransMedics Group during the fourth quarter valued at about $162,000. Virtu Financial LLC boosted its holdings in TransMedics Group by 467.7% during the fourth quarter. Virtu Financial LLC now owns 26,949 shares of the company’s stock valued at $3,278,000 after acquiring an additional 22,202 shares during the period. Summit Global Investments grew its position in shares of TransMedics Group by 3.6% in the fourth quarter. Summit Global Investments now owns 3,260 shares of the company’s stock valued at $397,000 after purchasing an additional 112 shares during the last quarter. Finally, EP Wealth Advisors LLC acquired a new stake in shares of TransMedics Group in the fourth quarter valued at about $210,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $78.79 on Monday. The firm’s 50-day moving average is $83.39 and its 200-day moving average is $112.53. The company has a market cap of $2.72 billion, a price-to-earnings ratio of 17.91 and a beta of 1.92. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. TransMedics Group, Inc. has a 52-week low of $60.10 and a 52-week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same quarter in the previous year, the business posted $0.70 EPS. The firm’s quarterly revenue was up 21.2% on a year-over-year basis. Equities research analysts anticipate that TransMedics Group, Inc. will post 1.98 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. UBS Group reiterated a “hold” rating on shares of TransMedics Group in a research note on Tuesday, May 26th. TD Cowen lowered their target price on TransMedics Group from $190.00 to $120.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Piper Sandler cut their price target on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. upped their price target on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $134.50.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.